Marketing that survives the approval process.
We are a pharmaceutical marketing agency running content, SEO, LinkedIn and paid media for regulated companies across Europe. Everything we publish is built to pass the same review your internal teams apply — because campaigns that cannot be approved never run.
Pharma marketing is constrained in ways most agencies discover halfway through a campaign: what can be claimed, who can be targeted, and what has to happen when someone reports a side effect in a comment.
Pharmaceutical marketing is defined by what is not allowed. Claims are bounded by the approved label, some channels reject pharma advertising outright, and anything published can generate an adverse-event report that has to be routed within a defined window.
SEO and content, social media and LinkedIn management, HCP and patient communications, paid media, email and CRM automation, conversion optimisation, analytics and employer branding.
Activity requiring a regulatory sign-off role we do not hold, advising on what may be claimed about a product, and acting as your pharmacovigilance function. We build the workflow; those responsibilities stay with you.
We maintain the platforms the campaigns land on, which is why measurement and follow-up do not fall apart at the handover. As a pharmaceutical marketing agency these figures describe the content operations we actually run.
An OTC brand can advertise to the public. A prescription-only laboratory cannot. That single distinction rewrites the entire pharmaceutical marketing plan.
What regulated companies ask before handing over a channel.
It depends on the product and the audience. Prescription-only medicines cannot be advertised to the public in the EU, and several platforms restrict pharmaceutical advertising further. Corporate, disease-awareness and professional-facing activity is generally possible, and that is where most of the opportunity sits.
With a defined routing procedure agreed with your pharmacovigilance team before the channel goes live: what counts as a report, who is notified, within what window, and what the moderator does in the meantime. We operate the process; the responsibility stays with your PV function.
Because the audience is there even though the use case is different. LinkedIn works well for professional engagement, recruitment, corporate positioning and partner visibility, none of which requires product advertising or a medical claim. In this sector it is frequently the channel where decision-makers and investors actively pay attention.
By involving them at planning rather than at approval. Most blocking happens because the first time legal sees an asset is when it is finished. Agreeing the boundaries up front — what can be claimed, which sources are acceptable, what needs review — turns approval into a check rather than a negotiation.
Yes, but the setup has to be built for it. That means server-side handling where appropriate, consent-aware configuration and accepting that some data is modelled rather than observed. The alternative — a tracking setup that quietly breaks after consent — is worse than measuring less.
Usually, and it changes the outcome more than clients expect. When one team runs both the platform and the campaigns, landing pages, conversion tracking and lead follow-up stay connected instead of splitting across two suppliers who each blame the other when a campaign underperforms. It also means changes reach the site the same week they are agreed.
Organic visibility, a social programme, HCP content or a campaign that keeps stalling in review. Tell us the context and we will tell you how we would approach the pharmaceutical marketing work.